Achieve Life Sciences Stock Forecast, Price & News

-0.01 (-0.11 %)
(As of 06/14/2021 11:40 AM ET)
Today's Range
50-Day Range
52-Week Range
Volume3,954 shs
Average Volume221,668 shs
Market Capitalization$53.63 million
P/E RatioN/A
Dividend YieldN/A
30 days | 90 days | 365 days | Advanced Chart
Receive ACHV News and Ratings via Email

Sign-up to receive the latest news and ratings for Achieve Life Sciences and its competitors with MarketBeat's FREE daily newsletter.

Achieve Life Sciences logo

About Achieve Life Sciences

Achieve Life Sciences, Inc., a clinical-stage pharmaceutical company, develops and commercializes of cytisinicline for smoking cessation and nicotine addiction in the United States and internationally. The company offers cytisinicline, a plant-based alkaloid that interacts with nicotine receptors in the brain to help reduce the severity of nicotine withdrawal symptoms. It has license agreements with Sopharma AD and University of Bristol. The company is based in Vancouver, Canada.


See More Headlines

Industry, Sector and Symbol

Sales & Book Value






Overall MarketRank

1.82 out of 5 stars

Medical Sector

188th out of 2,099 stocks

Diagnostic Substances Industry

3rd out of 35 stocks

Analyst Opinion: 3.5Community Rank: 2.7Dividend Strength: 0.0Insider Behavior: 1.7Valuation: 1.3 5 -4 -3 -2 -1 -
speech bubbles
speech bubbles

Achieve Life Sciences (NASDAQ:ACHV) Frequently Asked Questions

Is Achieve Life Sciences a buy right now?

4 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Achieve Life Sciences in the last twelve months. There are currently 4 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "buy" Achieve Life Sciences stock.
View analyst ratings for Achieve Life Sciences
or view top-rated stocks.

What stocks does MarketBeat like better than Achieve Life Sciences?

Wall Street analysts have given Achieve Life Sciences a "Buy" rating, but there may be better buying opportunities in the stock market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Achieve Life Sciences wasn't one of them. MarketBeat thinks these five companies may be even better buys.
View MarketBeat's top stock picks here.

Are investors shorting Achieve Life Sciences?

Achieve Life Sciences saw a decrease in short interest in the month of May. As of May 28th, there was short interest totaling 330,200 shares, a decrease of 22.9% from the May 13th total of 428,100 shares. Based on an average daily volume of 124,100 shares, the short-interest ratio is currently 2.7 days. Currently, 3.8% of the company's shares are short sold.
View Achieve Life Sciences' Short Interest

When is Achieve Life Sciences' next earnings date?

Achieve Life Sciences is scheduled to release its next quarterly earnings announcement on Thursday, August 5th 2021.
View our earnings forecast for Achieve Life Sciences

How were Achieve Life Sciences' earnings last quarter?

Achieve Life Sciences, Inc. (NASDAQ:ACHV) posted its quarterly earnings data on Wednesday, May, 12th. The biopharmaceutical company reported ($1.30) earnings per share (EPS) for the quarter, missing the Thomson Reuters' consensus estimate of ($0.78) by $0.52.
View Achieve Life Sciences' earnings history

How has Achieve Life Sciences' stock been impacted by COVID-19?

Achieve Life Sciences' stock was trading at $8.3240 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, ACHV shares have increased by 5.1% and is now trading at $8.75.
View which stocks have been most impacted by COVID-19

When did Achieve Life Sciences' stock split? How did Achieve Life Sciences' stock split work?

Shares of Achieve Life Sciences reverse split before market open on Friday, July 31st 2020. The 1-20 reverse split was announced on Thursday, July 30th 2020. The number of shares owned by shareholders was adjusted after the market closes on Thursday, July 30th 2020. An investor that had 100 shares of Achieve Life Sciences stock prior to the reverse split would have 5 shares after the split.

What price target have analysts set for ACHV?

4 brokers have issued 1-year target prices for Achieve Life Sciences' shares. Their forecasts range from $21.00 to $100.00. On average, they anticipate Achieve Life Sciences' stock price to reach $50.33 in the next twelve months. This suggests a possible upside of 475.2% from the stock's current price.
View analysts' price targets for Achieve Life Sciences
or view top-rated stocks among Wall Street analysts.

Who are Achieve Life Sciences' key executives?

Achieve Life Sciences' management team includes the following people:
  • Dr. Richard A. B. Stewart, Exec. Chairman (Age 62, Pay $699.48k)
  • Mr. John A. Bencich, CEO & Director (Age 44, Pay $620.52k)
  • Dr. Cindy Jacobs, Pres, Chief Medical Officer & Director (Age 63, Pay $579.81k)
  • Mr. Jerry Wan, Principal Accounting Officer (Age 39)
  • Dr. Anthony Clarke, Chief Scientific Officer (Age 65)
  • Ms. Jaime Xinos, Exec. VP of Commercial

Who are some of Achieve Life Sciences' key competitors?

What other stocks do shareholders of Achieve Life Sciences own?

What is Achieve Life Sciences' stock symbol?

Achieve Life Sciences trades on the NASDAQ under the ticker symbol "ACHV."

Who are Achieve Life Sciences' major shareholders?

Achieve Life Sciences' stock is owned by a number of institutional and retail investors. Top institutional shareholders include Morgan Stanley (1.42%), Geode Capital Management LLC (0.48%), Renaissance Technologies LLC (0.36%), Citadel Advisors LLC (0.20%), Citadel Advisors LLC (0.20%) and Paradigm Financial Partners LLC (0.18%).
View institutional ownership trends for Achieve Life Sciences

Which major investors are buying Achieve Life Sciences stock?

ACHV stock was bought by a variety of institutional investors in the last quarter, including Morgan Stanley, Geode Capital Management LLC, Renaissance Technologies LLC, Citadel Advisors LLC, Citadel Advisors LLC, and Paradigm Financial Partners LLC.
View insider buying and selling activity for Achieve Life Sciences
or or view top insider-buying stocks.

How do I buy shares of Achieve Life Sciences?

Shares of ACHV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Achieve Life Sciences' stock price today?

One share of ACHV stock can currently be purchased for approximately $8.75.

How much money does Achieve Life Sciences make?

Achieve Life Sciences has a market capitalization of $53.94 million. The biopharmaceutical company earns $-14,730,000.00 in net income (profit) each year or ($5.42) on an earnings per share basis.

How many employees does Achieve Life Sciences have?

Achieve Life Sciences employs 13 workers across the globe.

What is Achieve Life Sciences' official website?

The official website for Achieve Life Sciences is

Where are Achieve Life Sciences' headquarters?

Achieve Life Sciences is headquartered at 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1.

How can I contact Achieve Life Sciences?

Achieve Life Sciences' mailing address is 1040 WEST GEORGIA STREET SUITE 1030, VANCOUVER BC, V6E 4H1. The biopharmaceutical company can be reached via phone at 604-210-2217 or via email at [email protected]

This page was last updated on 6/14/2021 by Staff
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research. As a bonus to opt-ing into our email newsletters, you will also get a free subscription to the Liberty Through Wealth e-newsletter. You can opt out at any time.